NewTimeSpace News: On August 20, 2026, RoboSense (02498.HK) traded firmly in the afternoon. As of 15:12, the stock was quoted at HK$21.28, up 1.92%.
NewTimeSpace (newtimespace.com) News, On August 20, 2026, the chip theme moved in a volatile trend, with SMIC (00981.HK) paring gains after an intraday rally. As of 13:28, the company quoted HKD 72.000, down 1.37%.
NewTimeSpace (newtimespace.com) News, On August 20, 2026, the robot theme strengthened, while UBTECH ROBOTICS (09880.HK) traded weaker amid fluctuations. As of 13:11, the company quoted HKD 82.900, down 3.04%.
NewTimeSpace News: On 20 August 2026, SSY GROUP (02005.HK) voluntarily announced that its Vitamin K1 Injection (1ml:10mg) has obtained the NMPA drug production registration certificate, classified as Chemical Drug Category 3 and deemed to pass the consistency evaluation; the drug is a basic clinical medication widely used for bleeding prevention and emergency treatment.
NewTimeSpace News: On 20 August 2026, LEADS BIOLABS-B (09887.HK) voluntarily announced that the Phase II study abstract of Vimx™ (a PD-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line NSCLC therapy has been published on the WCLC website, with an ORR of 65.0% and DCR of 95.0% in 60 evaluable patients and an ORR of 77.4% in the squamous subgroup; updated data from follow-up exceeding seven months will be presented orally at WCLC on 14 September.
NewTimeSpace News: On 20 August 2026, GENFLEET-B (02595.HK) voluntarily announced that a three-arm parallel-controlled Phase II study of oral KRAS G12D inhibitor GFH375 has been initiated for patients with previously treated KRAS G12D-mutated pancreatic cancer, including two first-in-class combination regimens (with cachexia bispecific GFS202A and pan-RAS inhibitor GFH276); GFH375 previously obtained breakthrough therapy designation in China and US FDA fast track designation.
NewTimeSpace News: On 19 August 2026, LEADS BIOLABS-B (09887.HK) voluntarily announced that Oblenio Bio has exercised its option to retain the exclusive global license for LBL-051, with the Company to receive a one-time non-refundable fee of USD 10 million; LBL-051 is an immune reset candidate targeting BCMA, CD19 and CD3 for refractory autoimmune diseases.
On August 19, 2026, the Hang Seng Index rose 0.09%, the Hang Seng TECH Index fell 1.21%, and the Hang Seng China Enterprises Index rose 0.21%.AI concept stocks weakened across the board that day, with most individual stocks falling sharply.In the large-model segment, only MEITUAN-W rose 1.75% and TENCENT rose 1.08%; among the two front-runners, Z.AI fell 2.97% and MINIMAX-W fell 8.28%; BIDU-SW, dragged down by weaker-than-expected results, tumbled more than 11%, with ALIBABA and KUAISHOU-W following lower.
NewTimeSpace News: On 19 August 2026, BAIYUNSHAN PH (00874.HK) announced in an overseas regulatory announcement that its controlling subsidiary Tianxin Pharmaceutical's Citicoline Sodium Injection (2ml:0.25g, 4ml:0.5g) has obtained the Supplementary Drug Application Approval Notice from the NMPA, with both specifications passing the generic drug consistency evaluation and the 4ml:0.5g specification approved for addition with a new drug approval number.
NewTimeSpace News: On August 19, 2026, XPENG-W (09868.HK) weakened in the afternoon session. As of 15:27, the stock was quoted at HK$45.92, down 2.84%.
NewTimeSpace (newtimespace.com) News, on August 19, 2026, the chip theme weakened sharply, with HUA HONG GRACE (01347.HK) plunging amid volatility. As of 13:33, the company's quote stood at HK$112.900, down 12.41%.
NewTimeSpace (newtimespace.com) News, on August 19, 2026, the robot theme weakened sharply, with MIDEA GROUP (00300.HK) trading in a volatile session. As of 13:20, the company's quote stood at HK$96.250, flat on the day.
NewTimeSpace News: On 19 August 2026, ABBISKO-B (02256.HK) voluntarily announced that the IND application of its oral small-molecule pan-KRAS inhibitor ABSK211 has been approved by the NMPA, following FDA approval on 8 July; preclinical studies showed broad-spectrum inhibitory activity against multiple KRAS alterations and combination therapy potential.
NewTimeSpace News: On 18 August 2026, ALPHAMAB-B (09966.HK) announced that the NDA for Anbenitamab (KN026) plus HB1801 as first-line treatment for HER2-positive advanced breast cancer has been accepted by the NMPA under priority review; the pivotal Phase III study demonstrated significantly superior progression-free survival versus the standard of care.
NewTimeSpace News: On 18 August 2026, CSPC PHARMA (01093.HK) announced that the NDA for KN026 plus HB1801 as first-line treatment for HER2-positive advanced breast cancer has been accepted by the NMPA under priority review; the pivotal Phase III study showed significantly superior progression-free survival versus the standard of care.
On August 18, 2026, The Hang Seng Index rose 0.07%, the Hang Seng TECH Index fell 0.90%, and the Hang Seng China Enterprises Index edged up 0.16%. The Hong Kong market's total turnover was HK$255.5 billion, with southbound funds recording a net inflow of HK$14.001 billion.The large-model segment remained under pressure, with the two front-runners plunging: Z.AI (02513.HK) fell 13.30% and MINIMAX-W (00100.HK) fell 4.49%. TENCENT, MEITUAN-W and others continued to weaken, while ALIBABA-W (09988.HK) rose against the trend by 3.68%.
